Organogenesis Holdings Inc.

NASDAQ:ORGO

Drug Manufacturers - Specialty & Generic

Healthcare
$0.85 +3.21%

+$0.08 today

Market cap
$110.75M
Beta
1.33
P/E (TTM)
-1086.7
EPS (TTM)
-$0.00
52W Low $2.04High $7.08

Volume 0.86M

Average 1.49M

ORGO EBITDA Margin

EBITDA as a percentage of revenue.

Organogenesis Holdings Inc.NASDAQ: ORGO

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin narrows to -150.7%

EBITDA Margin was -150.7% in Q1 FY2026, down 128.2 pp from a year earlier. On a trailing-twelve-month basis it was 7.3%, up 8.1 pp year over year. Over 3 fiscal years it widened by 4.2 pp.

Context

  • EBITDA Margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 2 analysts of -86.1% for the fiscal year ending Dec 2026, down from 13.1% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-150.7%-182.0 pp QoQ
Last fiscal yearDec 2025
13.1%+9.9 pp YoY
LTMMar 2026
7.3%+8.1 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-128.2 pp-65.9 pp+62.3 pp
1 year+9.9 pp-99.2 pp-109.0 pp
3 years+4.2 pp-28.2 pp-32.3 pp
5 years——
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
13.1%
Year-over-year change
+9.9pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How ORGO compares with its peers on the latest reported figures

  • ORGO's LTM Mar 2026 EBITDA Margin of 7.3% is the 4th highest of the 9 companies compared; the peer median is 2.3%.
  • Its year-over-year change of +8.1 pp is the 5th highest of 9, against a peer median of +8.3 pp.
  • Over three fiscal years its change of +4.2 pp compares with a peer median of +29.8 pp.
ORGO Competitors Peer median
EBITDA Margin for ORGO and competitors
Company Period LTM level YoY 3-year change
SIGASIGA Technologies, Inc.LTM Mar 202629.3% -22.9 pp-7.6 pp
EBSEmergent BioSolutions Inc.LTM Mar 202622.8% +10.3 pp+31.0 pp
ESPREsperion Therapeutics, Inc.LTM Mar 20269.5% +43.6 pp+249.5 pp
ORGOOrganogenesis Holdings Inc.LTM Mar 20267.3% +8.1 pp+4.2 pp
SNDLSNDL Inc.LTM Mar 20265.3% +10.5 pp+50.9 pp
VREXVarex Imaging CorporationLTM Apr 2026-0.7% -9.9 pp-12.9 pp
ANGOAngioDynamics, Inc.LTM Feb 2026-1.7% -1.9 pp-2.9 pp
EOLSEvolus, Inc.LTM Mar 2026-4.6% +6.2 pp+28.7 pp
BCYCBicycle Therapeutics plcLTM Mar 2026-333.1% +482.9 pp+448.9 pp
MNPRMonopar Therapeutics Inc.FY2025— ——
CMPXCompass Therapeutics, Inc.FY2025— ——
Peer median (excluding ORGO) 2.3%+8.3 pp+29.8 pp

Competitors are the stored peer set for ORGO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue467.36M450.89M433.14M482.04M563.03M
Cost of Revenue114.2M105.02M106.48M115.74M137.52M
Gross Profit353.16M345.87M326.66M366.3M425.51M
Gross Margin75.6%76.7%75.4%76.0%75.6%
Research & Development30.74M39.76M44.38M50.27M44.54M
Selling, General & Admin250.2M283.81M269.75M294.51M326.24M
Operating Expenses280.94M323.57M314.13M367.59M369.64M
Depreciation & Amortization16.68M18.03M23.45M17.03M26.94M
EBITDA87M40.32M36.03M15.76M73.91M
EBITDA Margin18.6%8.9%8.3%3.3%13.1%
Operating Income72.22M22.3M12.53M(1.28M)55.87M
Operating Margin15.5%4.9%2.9%-0.3%9.9%
Interest Income00002.28M
Interest Expense7.24M2.01M2.19M1.54M0
Other Income / Expenses(9.13M)(2.02M)(2.13M)(1.52M)(8.9M)
Income Before Tax63.09M20.28M10.39M(2.81M)46.97M
Pre-Tax Margin13.5%4.5%2.4%-0.6%8.3%
Income Tax Expense(31.12M)4.75M5.45M(3.67M)9.94M
Net Income94.2M15.53M4.95M861K37.03M
Net Margin20.2%3.4%1.1%0.2%6.6%
EPS (Basic)0.730.120.04(0.01)0.16
EPS (Diluted)0.700.120.04(0.01)0.15
Weighted Avg Shares128.33M130.07M131.23M131.67M126.74M
Weighted Avg Shares (Diluted)133.66M132.38M132.75M131.67M130.25M

Organogenesis Holdings Inc.

NASDAQ:ORGO

Intrinsic Alpha fair value

Locked

Current Price

$0.85

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.